Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/21/2018 |
| Start Date: | April 2013 |
| End Date: | December 2020 |
| Contact: | Amy K Camblos |
| Email: | amycamblos@virginia.edu |
| Phone: | 434-243-1927 |
Hypofractionated Post-prostatectomy Radiotherapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase I/II Trial
Radiation therapy is one of the standard treatments for men with prostate cancer who have
detectable levels of prostate specific antigen (PSA, a prostate cancer specific marker) after
surgery. When radiation therapy is given to patients who have an increase in PSA after
surgery, it is called "salvage radiation therapy". Currently the standard radiation therapy
course length for this type of cancer is around 7 ½ -8 weeks. Sometimes, radiation therapy
after prostate removal causes unpleasant side effects. A shorter course of radiation therapy,
known as a "hypofractionated" course, gives fewer but higher doses of radiation than standard
radiation.
The purpose of this study is to test the safety of a shorter course of radiation therapy at
progressively lower dose levels and shorter lengths of treatment (hypofractionated) with
patients who have had their prostate removed. The study will assess whether the
hypofractionated course works better without causing additional side effects to the remaining
cancer cells in the prostate bed.
detectable levels of prostate specific antigen (PSA, a prostate cancer specific marker) after
surgery. When radiation therapy is given to patients who have an increase in PSA after
surgery, it is called "salvage radiation therapy". Currently the standard radiation therapy
course length for this type of cancer is around 7 ½ -8 weeks. Sometimes, radiation therapy
after prostate removal causes unpleasant side effects. A shorter course of radiation therapy,
known as a "hypofractionated" course, gives fewer but higher doses of radiation than standard
radiation.
The purpose of this study is to test the safety of a shorter course of radiation therapy at
progressively lower dose levels and shorter lengths of treatment (hypofractionated) with
patients who have had their prostate removed. The study will assess whether the
hypofractionated course works better without causing additional side effects to the remaining
cancer cells in the prostate bed.
Inclusion Criteria:
- diagnosis of prostate adenocarcinoma and
- have had a prostatectomy
- have detectable PSA
- 18 years of age or older
Exclusion Criteria:
- are receiving chemotherapy or other agents intended for cancer treatment
- history of rectal surgery or lower gastrointestinal bleed
- history of bleeding diathesis or abnormal sensitivity to ionizing radiation
- had prior pelvic irradiation or are scheduled to receive pelvic nodal irradiation
We found this trial at
3
sites
1215 Lee St
Charlottesville, Virginia 22903
Charlottesville, Virginia 22903
(434) 924-0211
Principal Investigator: Timothy Showalter, MD
University of Virginia Health System UVA Health System includes a 604-bed hospital, level I trauma...
Click here to add this to my saved trials
Click here to add this to my saved trials
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
Click here to add this to my saved trials